|Synonyms||Rabbit polyclonal to Synagis|
|Description||Palivizumab with trade name Synagis, is an FDA-approved drug for the prevention of respiratory syncytial virus (RSV) infections. It is a recombinant humanized IgG1 kappa isotype monoclonal antibody. Palivizumab binds the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process.
GenScript Anti-Palivizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Palivizumab.
|Purification||Antigen affinity purification|
|Concentration||0.5 mg/ml, lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.|
|Reconstitution||Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.|
|Specificity||The product is specific for Palivizumab.|
|Storage||The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.|
|Note||GenScript can customize this product per customer's request including product size, buffer components, etc.
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
|Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
ELISA detection: 0.05-1 µg/ml
Other applications: user-optimized
For more documents, please visit "Technical Support".